Studies on 99mTc-labeling of the modified fragment of human alfa-fetoprotein (P149-QY)

M. Maurin; P. Garnuszek; U. Karczmarczyk; M. Mirowski

doi:10.1007/s10967-007-6980-y

Jump to Content

Journal of Radioanalytical and Nuclear Chemistry

Volume/Issue:: Volume 275: Issue 1

Studies on ^99mTc-labeling of the modified fragment of human alfa-fetoprotein (P149-QY)

Authors:

M. Maurin

M. Maurin National Medicines Institute Department of Radiopharmaceuticals 30/34 Chełmska Street 00-725 Warsaw Poland

Search for other papers by M. Maurin in
Current site
Google Scholar
PubMed

P. Garnuszek

P. Garnuszek National Medicines Institute Department of Radiopharmaceuticals 30/34 Chełmska Street 00-725 Warsaw Poland

Search for other papers by P. Garnuszek in
Current site
Google Scholar
PubMed

U. Karczmarczyk

U. Karczmarczyk National Medicines Institute Department of Radiopharmaceuticals 30/34 Chełmska Street 00-725 Warsaw Poland

Search for other papers by U. Karczmarczyk in
Current site
Google Scholar
PubMed

, and

M. Mirowski

M. Mirowski Medical University Department of Pharmaceutical Biochemistry, Molecular Biology Laboratory 1 Muszyńskiego Street 90-151 Łódź Poland

Search for other papers by M. Mirowski in
Current site
Google Scholar
PubMed

View More View Less

Pages:: 101–107

Online Publication Date:: 06 Sep 2007

Publication Date:: 01 Jan 2008

Article Category:: Research Article

DOI:: https://doi.org/10.1007/s10967-007-6980-y

Restricted access

Abstract

The present study shows the development of ^99mTc-labeling of the P149-QY peptide, a modified fragment of human alpha-fetoprotein (hAFP), with the intention of potential application for diagnosis of AFP positive tumors. An efficient preparation of ^99mTc-labeled P149-QY using HYNIC was developed. It has been shown that the free sulfhydryl groups in P149-QY can be protected with N-ethylmaleimide, preventing the radiolabeled peptide from loss of its biological activity. The biodistribution studies revealed favorable pharmacokinetics and a better specificity to the mammary adenocarcinoma tumor for the SH-protected radiolabeled P149-QY peptide in comparison to the radioiodinated and to the directly ^99mTc-labeled peptide.

Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://akjournals.com/abstract/journals/10967/275/1/article-p101.xml
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Collapse
Expand

Journal of Radioanalytical and Nuclear Chemistry

Print ISSN:: 0236-5731

Online ISSN:: 1588-2780

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language	English
Size	A4
Year of Foundation	1968
Volumes per Year	1
Issues per Year	12
Founder	Akadémiai Kiadó
Founder's Address	H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher	Akadémiai Kiadó Springer Nature Switzerland AG
Publisher's Address	H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible Publisher	Chief Executive Officer, Akadémiai Kiadó
ISSN	0236-5731 (Print)
ISSN	1588-2780 (Online)